Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients with #EGPA, with a 50% reduction in #steroid dose in the study cohort. Abs#1427 #ACR20 @RheumNow #Vasculitis https://t.co/elr6VR7447